Strategic partnerships Alligator Bioscience maintains active co-development and license collaborations with Orion Corporation and Aptevo Therapeutics, plus out-licensed programs with Shanghai Henlius and Biotheus, presenting multiple near-term collaboration opportunities for pharma partners seeking BIS-targeted immunotherapies or platform-enabled antibody discovery.

Clinical-stage portfolio With several tumor-directed immuno-oncology candidates and the lead CD40 agonist mitazalimab, plus Neo-X-Prime and RUBY bispecific platforms, potential buyers or co-development sponsors can evaluate near-term translational assets and strategic partnerships across diverse immuno-oncology modalities.

Platform leverage ALLIGATOR-GOLD and FIND technologies enable extensive antibody discovery and optimization, offering a compelling value proposition for partners seeking rapid hit extension, affinity maturation, or customization of bispecific and monoclonal antibodies.

Global licensing exposure Existing international out-licensing activity and collaborations across Asia and Europe indicate a receptive market for additional regional deals, license extensions, or milestone-driven collaborations to accelerate clinical programs.

Financial and growth signal Revenue is modest with venture-style funding support, signaling room for sales acceleration through strategic partnerships, co-development deals, or milestone-rich collaborations that align with Alligator’s clinical milestones and platform-enabled assets.